Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome.
BACKGROUND: Matrix metalloproteinases play a role in regulating cardiac remodeling. We previously reported an association between tissue inhibitor of metalloproteinase 2 (TIMP-2) expression and mitral valve (MV) disease. However, the determinants and prognostic value of mitral TIMP2 after MV surgery...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3903512?pdf=render |
id |
doaj-33e65834d70a438a9ce36b6ce0636243 |
---|---|
record_format |
Article |
spelling |
doaj-33e65834d70a438a9ce36b6ce06362432020-11-24T21:16:57ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0191e8628710.1371/journal.pone.0086287Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome.Tsung-Hsien LinSheau-Fang YangChaw-Chi ChiuHo-Ming SuWen-Chol VoonChee-Yin ChaiWen-Ter LaiSheng-Hsiung SheuBACKGROUND: Matrix metalloproteinases play a role in regulating cardiac remodeling. We previously reported an association between tissue inhibitor of metalloproteinase 2 (TIMP-2) expression and mitral valve (MV) disease. However, the determinants and prognostic value of mitral TIMP2 after MV surgery are unknown. METHODS: This retrospective study of 164 patients after MV surgery in a tertiary medical center in Taiwan assessed mitral TIMP2 on a semiquantitative scale (0-2) by immunohistochemical staining. The primary endpoints were the composite of cardiovascular death and heart failure admission. RESULTS: Mean age was 50.4±13.7 years. After a mean follow-up period of 101±59 months, primary endpoints had occurred in 25 (15.2%) subjects. Patients with and without primary endpoint events significantly differed in terms of age (56.6±14.4 vs. 49.2±13.4 years, respectively; p = 0.013) and left ventricular end-systolic diameter (LVESD) (39.7±8.2 vs. 35.5±7.5 mm, p = 0.010) at surgery. The TIMP2 had a significant dose-dependent association with development of a primary endpoint (p = 0.002). Kaplan-Meier analysis showed that TIMP2 expression has a significant positive association with primary endpoint-free survival (log-rank test; p = 0.004). Cox regression analysis showed that independent predictors of primary endpoints were TIMP2 (hazard ratio [HR] 0.28; 95% confidence interval [CI] 0.12-0.65; p = 0.003), age (HR 1.05; 95% CI 1.02-1.09; p = 0.003) and LVESD (HR 1.05; 95% CI 1.01-1.10; p = 0.020). CONCLUSIONS: The lack of mitral TIMP2 expression is associated with increases in cardiovascular death and heart failure following MV surgery.http://europepmc.org/articles/PMC3903512?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tsung-Hsien Lin Sheau-Fang Yang Chaw-Chi Chiu Ho-Ming Su Wen-Chol Voon Chee-Yin Chai Wen-Ter Lai Sheng-Hsiung Sheu |
spellingShingle |
Tsung-Hsien Lin Sheau-Fang Yang Chaw-Chi Chiu Ho-Ming Su Wen-Chol Voon Chee-Yin Chai Wen-Ter Lai Sheng-Hsiung Sheu Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome. PLoS ONE |
author_facet |
Tsung-Hsien Lin Sheau-Fang Yang Chaw-Chi Chiu Ho-Ming Su Wen-Chol Voon Chee-Yin Chai Wen-Ter Lai Sheng-Hsiung Sheu |
author_sort |
Tsung-Hsien Lin |
title |
Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome. |
title_short |
Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome. |
title_full |
Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome. |
title_fullStr |
Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome. |
title_full_unstemmed |
Mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome. |
title_sort |
mitral tissue inhibitor of metalloproteinase 2 is associated with mitral valve surgery outcome. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
BACKGROUND: Matrix metalloproteinases play a role in regulating cardiac remodeling. We previously reported an association between tissue inhibitor of metalloproteinase 2 (TIMP-2) expression and mitral valve (MV) disease. However, the determinants and prognostic value of mitral TIMP2 after MV surgery are unknown. METHODS: This retrospective study of 164 patients after MV surgery in a tertiary medical center in Taiwan assessed mitral TIMP2 on a semiquantitative scale (0-2) by immunohistochemical staining. The primary endpoints were the composite of cardiovascular death and heart failure admission. RESULTS: Mean age was 50.4±13.7 years. After a mean follow-up period of 101±59 months, primary endpoints had occurred in 25 (15.2%) subjects. Patients with and without primary endpoint events significantly differed in terms of age (56.6±14.4 vs. 49.2±13.4 years, respectively; p = 0.013) and left ventricular end-systolic diameter (LVESD) (39.7±8.2 vs. 35.5±7.5 mm, p = 0.010) at surgery. The TIMP2 had a significant dose-dependent association with development of a primary endpoint (p = 0.002). Kaplan-Meier analysis showed that TIMP2 expression has a significant positive association with primary endpoint-free survival (log-rank test; p = 0.004). Cox regression analysis showed that independent predictors of primary endpoints were TIMP2 (hazard ratio [HR] 0.28; 95% confidence interval [CI] 0.12-0.65; p = 0.003), age (HR 1.05; 95% CI 1.02-1.09; p = 0.003) and LVESD (HR 1.05; 95% CI 1.01-1.10; p = 0.020). CONCLUSIONS: The lack of mitral TIMP2 expression is associated with increases in cardiovascular death and heart failure following MV surgery. |
url |
http://europepmc.org/articles/PMC3903512?pdf=render |
work_keys_str_mv |
AT tsunghsienlin mitraltissueinhibitorofmetalloproteinase2isassociatedwithmitralvalvesurgeryoutcome AT sheaufangyang mitraltissueinhibitorofmetalloproteinase2isassociatedwithmitralvalvesurgeryoutcome AT chawchichiu mitraltissueinhibitorofmetalloproteinase2isassociatedwithmitralvalvesurgeryoutcome AT homingsu mitraltissueinhibitorofmetalloproteinase2isassociatedwithmitralvalvesurgeryoutcome AT wencholvoon mitraltissueinhibitorofmetalloproteinase2isassociatedwithmitralvalvesurgeryoutcome AT cheeyinchai mitraltissueinhibitorofmetalloproteinase2isassociatedwithmitralvalvesurgeryoutcome AT wenterlai mitraltissueinhibitorofmetalloproteinase2isassociatedwithmitralvalvesurgeryoutcome AT shenghsiungsheu mitraltissueinhibitorofmetalloproteinase2isassociatedwithmitralvalvesurgeryoutcome |
_version_ |
1726015113850257408 |